Form 4: Silence Therapeutics Director Plans Major Share Boost

A director and 10% owner of Silence Therapeutics plc has pre-disclosed plans to significantly increase their indirect beneficial ownership through future purchases of American Depositary Shares.

Summary

• Richard Ian Griffiths, a Director and 10% Owner of Silence Therapeutics plc, reported future acquisitions of American Depositary Shares (ADSs).
• On July 31, 2025, 14,342 ADSs are to be acquired at a price of $6.18 per ADS.
• On August 1, 2025, an additional 4,034 ADSs are to be acquired at a price of $6.14 per ADS.
• These acquisitions, totaling 18,376 ADSs (equivalent to 55,128 ordinary shares), will increase his indirect beneficial ownership through Cream Capital Limited.
• Following these planned transactions, the total indirect beneficial ownership will be 11,825,861 ordinary shares.

Sentiment

Score: 8

Explanation: The pre-disclosure of significant future share acquisitions by a director and 10% owner indicates strong conviction in the company's long-term value and performance.

Positives

• The planned acquisition of a significant number of American Depositary Shares by a Director and 10% Owner signals strong confidence in the company's future prospects and valuation.
• The transactions will increase the insider's total indirect beneficial ownership to over 11.8 million ordinary shares, reinforcing alignment with shareholder interests.

Future Outlook

The filing indicates a positive future outlook from a key insider, as evidenced by their planned increase in shareholding.

Industry Context

This insider transaction reflects a specific company event and does not directly relate to broader industry trends or competitors, though strong insider confidence can indirectly influence sector sentiment.

Related Party Transactions

• The filing details the planned acquisition of shares by Richard Ian Griffiths, a director and 10% owner, through Cream Capital Limited, which he controls. Mr. Griffiths disclaims beneficial ownership except to the extent of his proportionate pecuniary interest therein.

Stakeholder Impact

• Shareholders may view this as a positive signal, potentially increasing investor confidence due to strong insider conviction.
• The increased ownership by a director aligns management's interests more closely with those of other shareholders.

Key Dates

Recommendation

The substantial planned purchases by a director who is also a 10% owner suggest strong conviction in the company's future value, making it a compelling 'strong buy' signal for investors.

Keywords

Silence Therapeutics, SLN, Form 4, insider buying, director purchase, stock acquisition, beneficial ownership, American Depositary Shares, Cream Capital Limited